Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
Esperion Therapeutics, Inc. (ESPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "Esperion Reports First Quarter 2023 Financial Results – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y&#59; New to Brand Prescriptions Grew 56% Q/Q –"
08/02/2022 8-K Quarterly results
Docs: "Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update – Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial&#59; On Track for Topline Results 1Q 2023 –"
05/03/2022 8-K Quarterly results
02/22/2022 8-K Quarterly results
Docs: "Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update – Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 –"
11/02/2021 8-K Quarterly results
Docs: "Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update – Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth –"
08/03/2021 8-K Quarterly results
Docs: "ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update – U.S. Net Product Revenue of NEXLETOL® Tablets and NEXLIZET® Tablets Grew 67% Sequentially to $10.6 Million –"
05/04/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update –Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® and NEXLIZET® tablets –"
08/10/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results ANN ARBOR, Mich., May 8, 2019 — Esperion today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019. “The potential of bempedoic acid is being broadly realized as evidenced by publication and presentation of Phase 3 clinical study results in the New England Journal of Medicine, the American College of Cardiology 2019 Scientific Sessions and other industry leading platforms. This high-profile external validation of the potential of bempedoic acid to meet the LDL-C lowering needs of the millions of patients with high LDL-C despite the use of currently accessible therapies confirms the beliefs of our Lipid Man..."
11/01/2018 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results ANN ARBOR, Mich., Nov. 01, 2018 — Esperion , the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2018. “The Lipid Management Team has made tremendous progress this year with positive top-line results reported from five pivotal Phase 3 studies. As we learned at our investor day in July, leading physicians and key opinion leaders have a highly favorable view of both bempedoic aci..."
08/02/2018 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2018 Financial Results Ann Arbor, Mich., — — Esperion , the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2018. “The Lipid Management Team has made tremendous progress during the first half of 2018, with positive top-line results reported from three pivotal Phase 3 studies and one Phase 2 study. Full results of completed Phase 3 studies are being prepared for presentation and publication, with full St..."
05/02/2018 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results Ann Arbor, Mich., — — Esperion , the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2018. “The Lipid Management Team has made tremendous progress in 2018, with positive top-line results reported from two pivotal, Phase 3 studies and one Phase 2 study. The growing body of clinical evidence continues to demonstrate the potential value of bempedoic acid and the bempedoic acid / ezeti..."
11/07/2017 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2017. “We are entering the most transformative period in Esperion's history in a strong position. The bempedoic acid franchise continues to deliver highly positive clinical results, most recently with the all-oral regimen of the bempedoic acid / ezetimibe combination plus ato..."
08/08/2017 8-K Quarterly results
Docs: "Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results"
05/04/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Quarterly results
Docs: "Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid development program updates and financial results for the second quarter ended June 30, 2016. “The Esperion team is focused on the fourth quarter initiation of our global pivotal Phase 3 CLEAR LDL-C lowering efficacy studies in patients with hypercholesterolemia and the global CLEAR Outcomes trial in statin intolerant patients,” said Tim Mayleben, president and chief executive officer of Esperion Therapeutics. “We also look forwa..."
05/04/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid development program updates and financial results for the fourth quarter and full year ended December 31, 2015. “The past year was eventful for Esperion, with positive clinical data reported from bempedoic acid as an ‘add-on' to statins and in patients with hypercholesterolemia and hypertension,” said Tim M. Mayleben, president and chief executive officer of Esperion. “With a stron..."
11/05/2015 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2015. “Our team remains focused and eager to advance the ETC-1002 development program into Phase 3 before year-end with the launch of our long-term safety study,” said Tim M. Mayleben, president and chief executive officer of Esperion. “We look forward to providing an update on our full Phase 3 plans in the first hal..."
08/06/2015 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2015. “Having successfully completed our Phase 2 program for ETC-1002, we are focused on the End-of-Phase 2 meeting with the FDA next week and the upcoming launch of a robust Phase 3 program..."
05/07/2015 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results Conference Call and Webcast Today, May 7, 2015 at 4:30 p.m. Eastern Time Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the first quarter ended March 31, 2015. “Esperion had another truly transformational quarter,” said Tim M. Mayleben, president and chief executive officer of Esperion. “Following the recently announced positive Phase 2b add-on to statin clinical st..."
03/05/2015 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast Today, Thursday, March 5, 2015, at 4:30 p.m. Eastern Time Ann Arbor, Mich., — — Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the fourth quarter and full year ended December 31, 2014. “The past year has been the most impactful yet for ETC-1002 and Esperion,” said Tim M. Mayleben, president and chief executive officer of Esperion. “Positive top-..."
11/10/2014 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results Conference Call and Webcast on Monday, November 10, 2014 at 4:30 p.m. Eastern Time Ann Arbor, Mich., —— Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014. “October proved to be truly transformational for Esperion. We announced positive top-line results from our Phase 2b ETC-1002-008 clinical trial in statin intolerant and statin tolerant patients, a..."
08/11/2014 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results Conference Call and Webcast on Tuesday, August 12, 2014 at 4:30 p.m. Eastern Time Ann Arbor, Mich., —— Esperion Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014. “Top-line results are expected in early October from our Phase 2b ETC-1002-008 clinical trial in statin intolerant patients. Results from our 2-year carcinogenicity studies are anticipated late..."
05/12/2014 8-K Quarterly results
Docs: "Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results"
11/06/2013 8-K Form 8-K - Current report
08/12/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy